Skip to content
Home/Companies/Healthcare/Ascend Gene & Cell Therapies
Ascend Gene & Cell Therapies

Ascend Gene & Cell Therapies

Healthcare·France·Active
Entry
–
Hold
–
Status
Active

Who owns Ascend Gene & Cell Therapies?

Ascend Gene & Cell Therapies is currently owned by Cathay Capital through Cathay Health (2021 vintage).

Hand-verified · updated 2026-04-21

Cathay Capital
Investor
Cathay Capital
Cathay Health · 2021 · Growth

Key facts

HQFrance
SectorHealthcare
Websitewww.ascend-adv.com

More from Cathay Health

Other portfolio companies in the same fund.

Ganymed Robotics
Ganymed Robotics
Active
MedTechFrance· 2022
Moon Surgical
Moon Surgical
Active
MedTechFrance· 2022
Initiate Studios
Initiate Studios
Active
HealthcareUS· 2021
Kojin Therapeutics
Exited 2025
BiotechUS· 2021
Tissium
Active
MedTechFrance· 2021

More PE-backed in Healthcare

Comparable healthcare deals from other GPs.

3i – Implant Innovations Inc.
Active
Advent InternationalUS
Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
Abode Healthcare
Active
Summit PartnersUS
AccentCare
AccentCare
Active
Advent InternationalUS
Acentra Health
Acentra Health
Active
The Carlyle GroupUS
AdipoPharma
AdipoPharma
Active
Capital Grand EstFrance
Track Ascend Gene & Cell Therapies

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Ascend Gene & Cell Therapies?

5 strategic and 115financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Ascend Gene & Cell Therapies.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue